Dianthus Therapeutics
Waltham
About Dianthus Therapeutics
Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach. DNTH103 is a new medicine in development for serious autoimmune diseases. It targets a specific part of the immune system and could be a self-administered injection for some patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $1.4B
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:DNTH
- Website: dianthustx.com
- Phone: 781-795-4723
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/dianthus-therapeutics-89900 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.